My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 351

    1.

    Drotrecogin alfa (activated): real-life use and outcomes for the UK.

    Rowan KM, Welch CA, North E, Harrison DA.

    Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.PMID: 18430215 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

    3.

    Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

    Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

    Crit Care Med. 2004 Nov;32(11):2207-18.PMID: 15640632 [PubMed - indexed for MEDLINE]Related articles

    4.

    Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

    Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

    Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.PMID: 15774234 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61. PMID: 17084715 [PubMed - indexed for MEDLINE]Related articles

    6.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.PMID: 17431957 [PubMed - indexed for MEDLINE]Related articles

    7.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.PMID: 18394162 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.PMID: 16192478 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.PMID: 18786266 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.PMID: 12544987 [PubMed - indexed for MEDLINE]Related articles

    11.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.PMID: 15640631 [PubMed - indexed for MEDLINE]Related articles

    12.

    The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R.

    Crit Care. 2009;13(3):R103. Epub 2009 Jun 30.PMID: 19566927 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

    Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

    Crit Care Med. 2005 May;33(5):952-61.PMID: 15891319 [PubMed - indexed for MEDLINE]Related articles

    14.

    Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

    Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RT, Yan SB, Wyss VL, Bailey JE, Mitchell CL, Sarwat S, Shinall SM, Janes JM.

    Crit Care. 2005 Aug;9(4):R331-43. Epub 2005 May 17.PMID: 16137345 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

    Camporota L, Corno E, Menaldo E, Smith J, Lei K, Beale R, Wyncoll D.

    Crit Care. 2008;12(6):R163. Epub 2008 Dec 18.PMID: 19094233 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.

    Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM.

    Curr Med Res Opin. 2007 Jan;23(1):235-44.PMID: 17207305 [PubMed - indexed for MEDLINE]Related articles

    17.

    Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

    Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

    Lancet. 2007 Mar 10;369(9564):836-43.PMID: 17350452 [PubMed - indexed for MEDLINE]Related articles

    18.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.PMID: 16895513 [PubMed - indexed for MEDLINE]Related articles

    19.

    From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

    Short MA, Schlichting D, Qualy RL.

    Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.PMID: 17265595 [PubMed - indexed for MEDLINE]Related articles

    20.

    Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

    Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

    Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.PMID: 12720562 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity